Frontiers in OncologyCancer BiologyPeer-reviewed journal article
A structure-based tool to interpret the significance of kinase mutations in clinical next generation sequencing in cancer
Amith Vikram RangarajaniD, Ilona Sviezhentseva, Emma L. GundersoniD, Yana PikmaniD, Matthew P. JacobsoniD, Beth Apsel WingeriD
Abstract
IntroductionClinical workflows to analyze variants of unknown significance (VUSs) found in clinical next generation sequencing (NGS) are labor intensive, requiring manual analysis of published data for each variant. There is a strong need for tools and resources that provide a consistent way to analyze variants. With the explosion of clinical NGS data and the concurrent availability of protein structures through the Protein Data Bank and protein models through programs such as AlphaFold, there exists an unprecedented opportunity to use structural information to help standardize NGS analysis with the overall goal of advancing personalized cancer therapy. MethodsUsing the Catalogue of Somatic Mutations in Cancer (COSMIC), the largest curated database of clinical cancer mutations, we mapped thousands of missense mutations in the kinase and juxtamembrane (JM) domains of 48 receptor tyrosine kinases (RTKs) onto structurally aligned kinase structures, then clustered known activating mutations along with VUSs based on proximity in three-dimensional structure. Using cell-based models we illustrate that our resource can be used to identify activating mutations and provide insight into mechanisms of kinase activation and regulation. ResultsWe provide a database of structurally aligned and functionally annotated mutations that can be used as a tool to evaluate kinase VUSs based on their structural alignment with known activating mutations. The tool can be accessed through a user-friendly website in which one can input a kinase mutation of interest, and the system will output a list of structurally analogous mutations in other kinases, as well as their functional annotations. DiscussionWe expect our database to be an important addition to the current tools and resources used to analyze clinical NGS, with important clinical implications to guide recommendations for personalized cancer therapy.
- organism: human
- assay: proteomics
- research focus: variant effect prediction
- approach: deep learning
- approach: statistical model
- Citations
- 0
- FWCI
- 0.00
- Field percentile
- 18th percentile
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Integrative machine learning predicts activating kinase mutations for precision oncology
Yiming Wang, Fang Wan, … Ravi Radhakrishnan·bioRxiv·Oct 14, 2025
- Truncation and Motif Based Pan-Cancer Analysis Highlights Novel Tumor Suppressing Kinases.
Andrew M. Hudson, Natalie L. Stephenson, … John Brognard·bioRxiv·Jan 27, 2018
- Protein structural context of cancer mutations reveals molecular mechanisms and identifies novel candidate driver genes
Diego Chillón Pino, Mihaly Badonyi, … Joseph A. Marsh·bioRxiv·Mar 21, 2024
- Discovery of oncogenic ROS1 missense mutations with sensitivity to tyrosine kinase inhibitors
S. R. Iyer, K. Nusser, … M. A. Davare·EMBO Molecular MedicinePeer-reviewed·Oct 11, 2023
- Prospective evaluation of structure-based simulations reveal their ability to predict the impact of kinase mutations on inhibitor binding
Sukrit Singh, Vytautas Gapsys, … John D. Chodera·The Journal of Physical Chemistry BPeer-reviewed·Mar 7, 2025
- How far are we in the rapid prediction of drug resistance caused by kinase mutations?
Mehmet Erguven, Tülay Karakulak, … Ezgi Karaca·ACS OmegaPeer-reviewed·Jan 4, 2021